JUBLPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 2.6
| Stock Code | JUBLPHARMA | Market Cap | 15,714 Cr. | Current Price | 986 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.51 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 1,034 ₹ | DMA 200 | 1,056 ₹ | Chg in FII Hold | -0.60 % |
| Chg in DII Hold | 0.70 % | PAT Qtr | -48.0 Cr. | PAT Prev Qtr | 4.10 Cr. | RSI | 46.6 |
| MACD | -26.8 | Volume | 1,54,176 | Avg Vol 1Wk | 1,16,822 | Low price | 802 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 41.1 % | Qtr Profit Var | -436 % |
| EPS | 1.15 ₹ | Industry PE | 29.2 |
📊 Based on the given parameters, Jubilant Pharmova (JUBLPHARMA) shows weak fundamentals with negative profitability and bearish technical indicators. It is a risky candidate for swing trading, suitable only for speculative short-term plays near strong support levels.
✅ Optimal Entry Price: Around 960–975 ₹ (near support and below 50 DMA)
📈 Exit Strategy if Holding: Consider booking profits near 1,020–1,040 ₹ (close to 50 DMA resistance), or cut losses if price falls below 950 ₹.
Positive
- 💡 Debt-to-equity ratio of 0.02 shows very low leverage and financial stability.
- 📈 Dividend yield of 0.51% provides minor investor incentive.
- 📊 DII holding increased (+0.70%), showing domestic institutional support.
- 🚀 Trading volume (1.54 lakh vs avg 1.16 lakh) indicates active participation.
Limitation
- ⚠️ ROCE (2.91%) and ROE (1.04%) are very weak, highlighting poor efficiency.
- 📉 EPS of 1.15 ₹ is extremely low relative to price.
- 📊 RSI at 46.6 indicates weak momentum, close to oversold zone.
- 📉 MACD negative (-26.8), confirming bearish short-term trend.
- 💰 No clear P/E ratio due to negative earnings, making valuation difficult.
Company Negative News
- ⚠️ Quarterly PAT turned negative (-48 Cr vs +4.1 Cr), showing earnings weakness.
- 📉 Profit variation (-436%) highlights severe decline in performance.
- 📊 FII holding decreased (-0.60%), signaling foreign investor caution.
Company Positive News
- 🚀 Domestic institutional buying interest supports sentiment.
- 📈 Strong trading activity despite weak fundamentals suggests speculative interest.
Industry
- 🌐 Pharma industry benefits from long-term demand in healthcare and global drug supply.
- 📊 Industry PE at 29.2 shows sector is moderately valued, but JUBLPHARMA’s weak earnings make comparison difficult.
- ⚠️ Sector faces risks from regulatory approvals, R&D costs, and global competition.
Conclusion
⚖️ Jubilant Pharmova is fundamentally weak with negative profitability and bearish technical indicators, though supported by low debt and domestic institutional interest. Entry near 960–975 ₹ offers a speculative swing setup, with exit targets around 1,020–1,040 ₹. Traders should maintain strict stop-loss discipline below 950 ₹ and monitor earnings recovery and institutional flows for confirmation.